The BIOTECH media, unfolded.
Biotechnology, gene editing, neurotech and computational biology.
123 reports across 1 topic, updated hourly.
Researchers have utilized predictions from the AI model AlphaFold3 to enhance the specificity of CRISPR genome-editing enzymes. Published online on July 22, 2026, in Nature, the study details how AlphaFold3's accurate predictions of molecular contacts within CRISPR complexes have been…
Biotech brand Re:You officially launched this week, introducing a line of three products designed to address hair thinning and promote hair vitality. The brand's core innovation is its proprietary AI-driven Novogro technology, which is central to the efficacy…
Researchers have engineered novel CRISPR proteins using artificial intelligence that exhibit superior efficiency in genome editing compared to their naturally occurring counterparts. This advancement was detailed in a study published online in Nature on July 17, 2026.
Gene therapy for neovascular age-related macular degeneration (nAMD) has demonstrated stable vision and retinal anatomy for up to five years in studies presented in Montreal. This innovative treatment approach has also led to dramatic reductions in the overall treatment burden…
Researchers have successfully designed novel CRISPR enzymes using artificial intelligence, creating "molecular scissors" with gene-editing capabilities not found in nature. This breakthrough, detailed in a publication on July 16, 2026, significantly expands the toolkit for genetic engineering.
Researchers have repurposed a bacterial self-destruct mechanism, utilizing CRISPR technology, to selectively eliminate diseased cells, including tumor cells in mouse models of cancer. This innovative approach, detailed in a publication on July 14, 2026, in Nature, leverages a DNA-shredding enzyme…
Researchers have identified a previously unknown immune backup system that significantly enhances the effectiveness of mRNA cancer vaccines. This discovery overturns a long-held assumption about how these vaccines stimulate anti-tumor responses.
Dolly the sheep, the first mammal cloned from an adult somatic cell, continues to hold significant relevance in discussions surrounding reproductive technologies and gene editing, over 30 years after her birth on July 5, 1996.
Delays in bringing biotech breakthroughs to market are predominantly caused by communication breakdowns rather than scientific or regulatory challenges, according to an analysis published this week. The research highlights that while scientific innovation and navigating regulatory pathways are complex…
The U.S. Food and Drug Administration (FDA) expanded the approval for exagamglogene autotemcel (exa-cel), marketed as Casgevy, on Wednesday. This gene therapy is now approved for individuals as young as 2 years old who have severe sickle cell disease…
N4-acetylcytidine has been identified as a superior modification for synthetic messenger RNA (mRNA) translation, outperforming the current industry standard, N1-methylpseudouridine. This discovery, published online in Nature on July 1, 2026, demonstrates that different RNA modifications elicit distinct translation elongation rates…
CRISPR technology is evolving beyond direct DNA editing to target the epigenome, offering a new frontier for treating genetic diseases. This approach focuses on modifying gene expression without altering the underlying DNA sequence, a development detailed in a recent publication…
Several start-up companies are advancing therapies that directly edit the epigenome to address a variety of diseases. These novel treatments aim to modify gene expression without altering the underlying DNA sequence, targeting specific epigenetic markers that contribute to illness.
Base editing research published in Nature on June 25, 2026, has revealed the essential role of the NANOG gene in human embryogenesis. The study utilized advanced base editing techniques to precisely modify the NANOG gene, allowing researchers to observe…
On June 30, 2026, science editor Mary Beth Griggs and senior biotechnology reporter Jessica Hamzelou participated in a discussion exploring cellular reprogramming as a leading approach in longevity research. This emerging field focuses on "reprogramming" cells to revert them…
Clive Meanwell, a seasoned investor with nearly four decades of experience in drug development and biotech, is now focusing on designing biopharmaceutical companies with the explicit goal of improving population health.
The U.S.-China biotech relationship is facing increased scrutiny, with concerns about intellectual property theft and state-run companies impacting scientific collaboration. The author, who has covered the biotech and pharma sector for nearly two decades, notes a significant shift in China's…